

### Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

### Listing of Claims

1. (Currently amended) A purified or isolated protein comprising a 55 ~~Kd~~ kD polypeptide (~~p55~~) from *Neisseria gonorrhoeae*, wherein the molecular weight of the 55 kD polypeptide is determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions.
- 2-6. (Canceled)
7. (Currently amended) A ~~p55~~ purified or isolated protein ~~having an~~ comprising the amino acid sequence ~~that corresponds essentially to~~ of SEQ ID NO:4.
- 8-14. (Canceled)
15. (Currently amended) A vaccine comprising an immunogenic amount of  
(a) a 55 kD polypeptide p55 from *Neisseria gonorrhoeae*, wherein the molecular weight of the 55 kD polypeptide is determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions; or  
(b) a polypeptide comprising the amino acid sequence of SEQ ID NO:4,  
which in combination with a physiologically acceptable, non-toxic vehicle, wherein the amount is effective to immunize a susceptible female patient against gonorrhea, in  
~~combination with a physiologically acceptable, non-toxic vehicle.~~
- 16-20. (Canceled)
21. (Original) The vaccine of claim 15, wherein the polypeptide is expressed from an isolated nucleic sequence encoding the polypeptide.
22. (Canceled)

23. (Original) The vaccine of claim 15, which further comprises an effective amount of an immunological adjuvant.
24. (Original) The vaccine of claim 15, wherein the polypeptide is conjugated or linked to a second peptide.
25. (Original) The vaccine of claim 15, wherein the polypeptide is conjugated or linked to a polysaccharide.
- 26-59. (Canceled)